Sep 09, 2022

Mabwell and Yuanxin Technology Cooperate to Establish a Comprehensive Innovative Marketing Model

➞

Aug 23, 2022

Mabwell's Innovative Drug 6MW3511 Injection is Approved for Clinical Trial

➞

Aug 17, 2022

Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for JUNMAIKANG® (Adalimumab)

➞

Jul 29, 2022

Mabwell’s anti-Nectin-4 ADC drug received FDA’s IND Approval

➞

Jul 27, 2022

Mabwell Included in the List of 2021 New Shanghai Technology Innovation Center

➞

Jul 14, 2022

Mabwell and PKUCare Luzhong Hospital Established a Strategic Alliance

➞

Jun 17, 2022

The IND Application for 6MW3511 Injection - An Innovative Drug from Mabwell is Accepted by NMPA

➞

Mar 28, 2022

Achievements in Scientific Research | Mabwell Published ADE Mechanism of SARS-CoV-2 Neutralizing Antibodies in Communications Biology

➞

Mar 08, 2022

Facilitate Development and Accelerate Progress | Zhangjiang Town Leaders Visit Mabwell Bioscience to Research and Guide Work

➞

Mar 03, 2022

Good News! Mabwell's First Drug Adalimumab Approved for Marketing

➞